RCS - Angle PLC - Harvesting CTCs from brain metastasis patients

AngleAnnouncement

09/07/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210709:nRSI6606Ea&default-theme=true

RNS Number : 6606E  Angle PLC  09 July 2021

 

 For immediate release  09 July 2021

 

ANGLE plc ("the Company")

 

PARSORTIX USED TO SUCCESSFULLY HARVEST CANCER CELLS FOR ANALYSIS FROM THE
BLOOD OF PATIENTS WITH BRAIN METASTASIS

 

Parsortix successful in overcoming challenges associated with isolating CTCs
from brain metastasis patients in three different cancer types

 

Analysis of CTCs may enable more personalised care for cancer patients with
brain metastasis where traditional tissue biopsy is not possible

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is
pleased to announce that University Medical Centre Hamburg-Eppendorf has
published results of new work undertaken in patients with brain metastasis
demonstrating use of ANGLE's Parsortix(®) system in the isolation of
circulating tumour cells (CTCs). In addition, the research investigated the
role of two proteins, CD74 and CD44, in the development of brain metastasis.

 

Liquid biopsy from peripheral blood is a particularly attractive solution in
brain cancer because of the difficulty, medical complications and cost
associated with taking a tissue biopsy from the brain. The characterisation of
metastatic tumour cells can be crucial in helping to inform personalised
treatment decisions, but, because of the serious risks involved, most patients
with brain metastasis will never undergo a tissue biopsy unless undergoing
surgical tumour resection.

 

Historically, detection of CTCs from peripheral blood in brain metastasis has
been hampered by the blood-brain-barrier which results in fewer CTCs in
peripheral blood compared to other metastatic sites and, because these CTCs
have a more mesenchymal state, they are poorly detected using antibody-based
systems. In this study, 44 patients with primary breast cancer, non-small cell
lung cancer (NSCLC) and melanoma with subsequent brain metastases were
screened for CTCs using the Parsortix system. CTCs were detected in 50% of
breast cancer patients, 50% of NSCLC patients and 36% of melanoma patients.
CTC positivity rates were superior when compared to previous studies into
cancer brain metastases which utilised other CTC enrichment technologies,
including the leading antibody-based system where positivity rates of 20-22%
in breast cancer and 12.5% in NSCLC have been reported.

 

Brain metastases are the most common type of brain tumour accounting for 88%
of all new cases. The incidence of cancer brain metastases is increasing as
new therapeutics, advanced imaging, and improved screening have led to
increased survival following a primary diagnosis of cancer with approximately
200,000 new cases of brain metastases being diagnosed in the United States
each year.

 

Brain metastases are a significant cause of morbidity and mortality in
patients. Prognosis is poor with life expectancy usually less than a year and
a five-year survival rate of only 2.4%. In addition, brain metastases are
associated with loss of cognitive and sensory function and, in many patients,
lead to a significant reduction in quality of life.

 

This study further confirms the utility of the Parsortix system for the
isolation and characterisation of CTCs in brain metastases and that a
Parsortix-based blood test may provide additional medical information to
inform treatment decisions that could otherwise only be obtained by a highly
invasive tissue biopsy of the patient's brain.

 

The research has been published as a peer-reviewed publication in the
International Journal of Molecular Sciences and may be accessed via
https://angleplc.com/library/publications/
(https://angleplc.com/library/publications/) .

 

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"This is important new work by the world-leading Hamburg-Eppendorf cancer
centre. Prof. Wikman and her team have demonstrated the utility of the
Parsortix(®) system in isolating CTCs from cancer brain metastases and
demonstrated superior CTC positivity rates than those seen in studies using
other enrichment technologies. Cancer brain metastases cannot be accessed for
tissue biopsy without highly invasive procedures and a liquid biopsy
alternative would be of great benefit to patients to monitor and optimise
treatment."

 

 

For further information:

 

 ANGLE plc                                                    +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Andrew Holder, Head of Investor Relations

 finnCap Ltd (NOMAD and Joint Broker)                         +44 (0)20 7220 0500

 Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley

 ECM - Alice Lane, Sunila de Silva

 WG Partners (Joint Broker)                                   +44 (0) 203 705 9330

 Nigel Barnes, Nigel Birks

 FTI Consulting

 Simon Conway, Ciara Martin                                   +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                                     +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/

 

Notes for editors

 

About ANGLE plc www.angleplc.com (http://www.angleplc.com/)

ANGLE is a world leading liquid biopsy company with sample-to-answer
solutions. ANGLE's proven patent protected platforms include a circulating
tumor cell (CTC) harvesting technology and a downstream analysis system for
cost effective, highly multiplexed analysis of nucleic acids and proteins.

 

ANGLE's cell separation technology is called the Parsortix(®) system, and it
enables a liquid biopsy (a simple blood test) to be used to provide the cells
of interest to the user in a format suitable for multiple types of downstream
analyses. The system is based on a microfluidic device that captures cells
based on a combination of their size and compressibility.  The system is
epitope independent and can capture all types of CTCs as well as CTC clusters
in a viable form (alive).  CTCs enable the complete picture of a cancer to be
seen as being an intact cell they allow DNA, RNA and protein analysis and may
provide comparable analysis to a tissue biopsy. Because CTC analysis is a
non-invasive process, unlike tissue biopsy, it can be repeated as often as
needed. This is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the status of a
patient's tumor. In addition, the live CTCs harvested by the Parsortix system
can be cultured, which offers the potential for testing tumor response to
drugs outside the patient.

 

The Parsortix technology is the subject of 26 granted patents in Europe, the
United States, China, Australia, Canada, India, Japan and Mexico with three
extensive families of patents are being progressed worldwide.

 

The Parsortix system has a CE Mark in Europe for the indicated use and, in the
United States, a De Novo Submission has been made to FDA for the Parsortix(®)
PC1 system seeking FDA clearance with Class II Classification for use with
metastatic breast cancer patients. FDA clearance is seen as the global
standard. ANGLE is seeking to be the first ever FDA cleared system for
harvesting CTCs for subsequent analysis.

 

ANGLE has also completed two separate 200 subject clinical studies under a
program designed to develop an ovarian cancer pelvic mass triage test, with
the results showing best in class accuracy (AUC-ROC) of 95.1%.  The pelvic
mass triage assay has undergone further refinement and optimisation and is
currently in the process of a 200-patient clinical verification study.

 

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids
of all types is called the HyCEAD(TM) Ziplex(®) platform and is based on a
patented flow through array technology.  It provides for low cost, highly
multiplexed, rapid and sensitive capture of targets from a wide variety of
sample types. A proprietary chemistry approach (the HyCEAD method) allows for
the capture and amplification of over 100 biomarkers simultaneously in a
single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal
for measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test to achieve
best in class accuracy (AUC-ROC) of 95.1%.

 

ANGLE's proprietary technologies can be combined to provide automated,
sample-to-answer results in both centralised laboratory and point-of-use
cartridge formats.

 

ANGLE has established formal collaborations with world-class cancer centres
and major corporates such as Abbott, Philips and QIAGEN, and works closely
with leading CTC translational research customers.  These Key Opinion Leaders
(KOLs) are working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates that
utility in patient studies. The body of evidence as to the benefits of the
Parsortix system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with 46
peer-reviewed publications and numerous publicly available posters, available
on our website.

 

ANGLE has established clinical services laboratories in the UK and USA to
accelerate commercialisation of the Parsortix system and act as demonstrators
to support product development. The laboratories offer services to
pharmaceutical and biotech customers for use of the Parsortix system in cancer
drug trials and, once the laboratories are accredited, and tests validated,
will provide Laboratory Developed Tests (LDTs) for patient management.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAXVLFBFDLFBBZ